News & Events
(AUSTIN) Today, the Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), held a special meeting to approve a slate of awards totaling $48,923,075 for cancer research and product development. The list of grants is included at the bottom of this release.
“Today, the CPRIT Oversight Committee raised the bar on the fight against cancer,” said CPRIT CEO Wayne Roberts. “These grants continue to fund the path forward for cancer research in the state of Texas and provide vital financial support for the researchers, labs and institutions on the frontline of this monumental statewide effort to end cancer as we know it.”
CPRIT is proud to announce our Innovations in Cancer Prevention and Research Conference VI returns in-person October 2 - 3, 2023 at Moody Gardens Hotel, Spa and Convention Center in beautiful Galveston, Texas. (more)
CPRIT announces the release of four (4) Requests for Applications (RFAs) for FY 2023 Product Development Research grants. Complete RFAs and instructions are available in the “Apply for Funding” section of CPRIT’s website.
• Texas Therapeutics Company Product Development Research Award (TTC)
• Texas Diagnostics and Devices Company Product Development Research Award (TDDC)
• Texas New Technologies Company Product Development Research Award (TNTC)
• Seed Awards for Product Development Research (SEED)
(AUSTIN) Today, in a meeting at the State Capitol, the Oversight Committee of the Cancer Prevention and Research Institute of Texas (CPRIT), approved a large slate of awards totaling over $89 million for cancer research, prevention and product development. The list of grants is included below.
“The awards approved today by the Oversight Committee illustrate the depth and breadth of CPRIT's impact in the Texas fight against cancer,” said CPRIT CEO Wayne Roberts. “From recruitment grants bringing the brightest cancer researchers to Texas, to supporting lifesaving prevention programs across the state and providing critical investments in developing new cancer-fighting drugs, CPRIT touched all the bases for a home run against cancer.”
Last week, President Biden nominated Dr. Monica Bertagnolli to lead the National Cancer Institute. An accomplished surgical oncologist and scientist, Dr. Bertagnolli is the first woman to hold this post.
As NCI and CPRIT are the top two public funders of cancer research in the world, CPRIT CEO Wayne Roberts has sent the White House an official letter to add his voice to those supporting Dr. Bertagnolli's nomination.
At its meeting on May 18, 2022, CPRIT’s Oversight Committee approved four FY 2023 requests for applications (RFAs) for the Product Development Research program. The Oversight Committee also approved changes to the product development application and review process for the FY 2023 review cycle.
The Texas Comptroller’s Office is currently reviewing the proposed Product Development Program RFAs. CPRIT will release the RFAs after the Comptroller’s review, which we expect to occur in July. CPRIT staff plan to open the portal to receive preliminary applications in August. (more)